Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Anti-Parkinson Drugs Market Expected to Grow Between 2025 And 2029?

The market size for anti-Parkinson’s drugs has seen robust growth in the past few years. The market is projected to expand from $10.37 billion in 2024 to $11.08 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. The escalating trend during the historical period can be credited to factors such as the aging population, a rise in disease incidence, improvements in healthcare infrastructure, and advancements in medical research.

What Growth Rate Is Anticipated for the Anti-Parkinson Drugs Market in the Coming Years?

The market for anti-Parkinson’s medication is anticipated to witness considerable expansion in the upcoming years, forecasted to reach a value of $13.73 billion by 2029, growing at an annual compounded rate of 5.5%. This predicted growth in the forecast period is largely owing to increasing awareness, advancements in biotechnology, and the emergence of new markets. The forecast period is also expected to see trends such as investments in research and development, personalized medical treatments, therapies that modify diseases, drug repurposing, application of telemedicine and remote supervision, use of biosimilars, and research collaborations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

Who Are the Leading Companies in the Anti-Parkinson Drugs Market?

Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

What Are the Key Drivers of the Anti-Parkinson Drugs Market?

The rising elderly population, along with escalating instances of Parkinson’s disease (PD), typically seen in individuals above 60, is expected to fuel the demand in the anti-Parkinson drugs market. The World Health Organization, a US health agency, reported in October 2022 that by 2030, 1 in every 6 people worldwide will be 60 or older. This number is anticipated to double by 2050, reaching 2.1 billion. These factors point towards a growing geriatric population, thereby boosting the growth of the anti-Parkinson drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3462&type=smp

What Are the Key Market Segments in the Anti-Parkinson Drugs Industry?

The anti-parkinson drugs market covered in this report is segmented –

1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs

2) By Route of Administration: Oral, Injection, Transdermal

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Subsegments:

1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa

2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine

3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide

4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone

5) By Anticholinergics: Benztropine, Trihexyphenidyl

6) By Other Drugs: Amantadine, Apomorphine

What Are the Latest Trends in the Anti-Parkinson Drugs Market?

Major firms in the anti-Parkinson medication market are concentrating on the development of superior treatment solutions such as motor fluctuations and dyskinesia, aimed at improving symptom control and reducing side effects. These motor fluctuations and dyskinesia often add complexity to Parkinson’s disease treatment and impact patient wellness. Illustratively, in January 2024, AbbVie Inc., a pharmaceutical company based in the US, introduced PRODUODOPA. PRODUODOPA (foslevodopa/foscarbidopa) is a unique subcutaneous 24-hour infusion therapy for advanced Parkinson’s disease, specifically targeting severe motor fluctuations and dyskinesia when alternative therapies are ineffective. It provides a continuous supply of levodopa, potentially extending the ‘on’ period and enhancing symptom control.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

What Are the Key Regional Markets in the Anti-Parkinson Drugs Industry?

North America was the largest region in the anti-Parkinson drugs market in 2023. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3462

This Report Delivers Insight On:

1. How big is the anti-parkinson drugs market, and how is it changing globally?

2. Who are the major companies in the anti-parkinson drugs market, and how are they performing?

3. What are the key opportunities and risks in the anti-parkinson drugs market right now?

4. Which products or customer segments are growing the most in the anti-parkinson drugs market?

5. What factors are helping or slowing down the growth of the anti-parkinson drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model